36516 Federal Register / Vol. 87, No. 117 / Friday, June 17, 2022 / Notices 

1For the purpose of this request for information, 

the term ‘‘jurisdiction’’ includes the District of 

Columbia, the Republic of the Marshall Islands, the 

Federated States of Micronesia, the Republic of 

Palau, the Commonwealth of Puerto Rico, the 

Virgin Islands, Guam, American Samoa, and the 

Commonwealth of the Northern Mariana Islands. 

2For the purpose of this request for information, 

the EHDI system is defined as ‘‘families, consumers, 

providers, services, and programs that work 

towards developing coordinated and 

comprehensive state and territory systems so that 

families with newborns, infants, and young 

children who are deaf or hard of hearing receive 

appropriate and timely services that include 

hearing screening, diagnosis, and intervention.’’ 

Early Hearing Detection and Intervention Program 

Notice of Funding Opportunity HRSA–20–047’’? 

CBs who conduct food safety audits of 

foreign eligible entities that offer food 

for import to the United States. We also 

estimate the 208 accredited CBs will 

participate in the third-party program. 

In addition, we expect that one CB will 

apply and participate in the third-party 

program via direct accreditation by 

FDA. Finally, we attribute nominal 

burden to recordkeeping attendant to 

contractual modifications that may be 

part of accreditation. 

Based on a review of the information 

collection since last OMB approval, we 

have made only nominal adjustments to 

our burden estimate. 

Dated: June 13, 2022. 

Lauren K. Roth, 

Associate Commissioner for Policy. 

[FR Doc. 2022–13071 Filed 6–16–22; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Request for Information: Early Hearing 

Detection and Intervention Program 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services. 

ACTION: Notice of request for public 

comment. 

SUMMARY: HRSA’s Early Hearing 

Detection and Intervention (EHDI) 

Program is requesting input from the 

public to inform future EHDI program 

development. 

DATES: Submit comments no later than 

July 18, 2022. 

ADDRESSES: Submit electronic 

comments to ehdi@hrsa.gov. Please 

submit your response only one time by 

July 18, 2022. 

FOR FURTHER INFORMATION CONTACT: 

Sandra Battiste, MPH at ehdi@hrsa.gov 

or (301) 443–0223. 

SUPPLEMENTARY INFORMATION: HRSA’s 

EHDI Program, authorized under 42 

U.S.C. of the Public Health Service Act, 

seeks to enable states, jurisdictions, 

families, and clinical, educational, and 

social service providers to develop 

coordinated systems of care so that 

newborns, infants, and young children 

who are deaf or hard of hearing are 

identified as early as possible and 

receive the services they need. Early 

involvement can help these children 

meet age-appropriate language, literacy, 

social-emotional, and other 

developmental milestones. HRSA 

currently funds 59 states and 

jurisdictions 1 through the EHDI grants 

program in order to (1) increase health 

professionals’ engagement with and 

knowledge of the EHDI system,2 (2) 

improve access to early intervention 

services and language acquisition, and 

(3) improve family engagement, 

partnership, and leadership in EHDI 

systems. The HRSA-funded National 

Technical Resource Center supports 

states and territories by providing 

technical assistance and resources in 

order to meet EHDI program goals and 

objectives. 

HRSA investments also support 

family engagement and workforce 

development related to EHDI. For 

example, the Family Leadership in 

Language and Learning program aims to 

strengthen family leadership and 

inclusion of families, parents and 

caregivers of children who are deaf or 

hard of hearing within the EHDI system. 

In addition, HRSA funds the Leadership 

Education in Neurodevelopmental and 

Related Disabilities program, authorized 

under the Public Health Service Act, to 

support workforce development through 

audiology training grants. More 

information about the HRSA EHDI 

program is available online at: https://

mchb.hrsa.gov/maternal-child-healthinitiatives/early-hearing-detection-andintervention.html. 

Responses 

HRSA is seeking responses that 

address the following questions. A 

response to each question is not 

required. 

1. What strategies or programs are 

needed to support EHDI programs to 

ensure that all newborns are screened 

by 1 month of age, a diagnosis is made 

by 3 months of age, and children who 

are deaf or hard of hearing are enrolled 

in and start to receive intervention 

services by 6 months of age? 

2. What strategies should be 

considered to support the timely 

identification and receipt of services for 

young children up to age 3? 

3. What strategies should be 

considered to ensure that infants and 

young children receive screening and 

diagnosis services that are high quality 

and evidence-based? 

4. What strategies should be 

considered to ensure that providers 

collect and report high quality data on 

hearing screening, diagnosis, and 

follow-up to EHDI programs for public 

health surveillance? 

5. What strategies or programs would 

ensure that families of children who are 

deaf or hard of hearing receive 

information that is accurate, 

comprehensive, up-to-date, and 

evidence-based, as appropriate, to allow 

families to make important decisions for 

their children in a timely manner, 

including decisions with respect to the 

full range of assistive hearing 

technologies and communications 

modalities, as appropriate? 

6. What strategies would help ensure 

families, parents, and caregivers are 

continuously engaged as active partners 

in the EHDI system? 

7. What approaches that foster familyto-family and deaf and hard of hearing 

consumer-to-family supports by families 

and adults who are deaf or hard of 

hearing should be considered? 

8. What new evidence-based or 

promising approaches that help deaf or 

hard of hearing children meet language, 

literacy, social, emotional, and other 

developmental milestones should be 

considered within EHDI Programs/the 

EHDI system? 

9. How has COVID–19 impacted the 

EHDI system of care, including the 

ability of EHDI programs to share or 

report information in a timely manner? 

Are there any notable promising 

practices or approaches used in 

response that should be further 

explored? 

10. What ongoing and emerging gaps 

in access to services are present within 

the EHDI system? Are there populations 

that are experiencing inequities in 

access to timely identification and 

receipt of services? What approaches 

should be used to address these gaps? 

Respondents can also provide 

additional comments or 

recommendations that are not 

specifically linked to the questions 

above. All responses may but are not 

required to identify the individual’s 

name, address, email, telephone 

number, professional or organizational 

affiliation, background or area of 

expertise (e.g., program participant, 

family member, clinician, public health 

worker, researcher, EHDI Coordinator, 

etc.), and topic/subject matter. 

Information obtained as a result of this 

request for information (RFI) may be 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 87, No. 117 / Friday, June 17, 2022 / Notices 36517 

used by HRSA on a non-attribution 

basis for program planning. Comments 

in response to this RFI will be made 

publicly available, so respondents 

should bear this in mind when making 

comments. HRSA will not respond to 

any individual comments. 

Special Note to Commenters 

Whenever possible, respondents are 

asked to draw their responses from 

objective, empirical, and actionable 

evidence and to cite this evidence 

within their responses. 

The information obtained through this 

RFI may help inform the next iteration 

of the HRSA EHDI program portfolio of 

investments. This RFI is issued solely 

for information and planning purposes; 

it does not constitute a Request for 

Proposal, applications, proposal 

abstracts, or quotations. This RFI does 

not commit the U.S. Government to 

contract for any supplies or services or 

make a grant or cooperative agreement 

award. Further, HRSA is not seeking 

proposals through this RFI and will not 

accept unsolicited proposals. HRSA will 

not respond to questions about the 

policy issues raised in this RFI. 

Responders are advised that the U.S. 

Government will not pay for any 

information or administrative costs 

incurred in response to this RFI; all 

costs associated with responding to this 

RFI will be solely at the interested 

party’s expense. Not responding to this 

RFI does not preclude participation in 

any future procurement or program, if 

conducted. 

Diana Espinosa, 

Deputy Administrator. 

[FR Doc. 2022–13037 Filed 6–16–22; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Respiratory Sciences. 

Date: July 12–13, 2022. 

Time: 9:00 a.m. to 12:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Eugene Carstea, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4130, 

MSC 7818, Bethesda, MD 20892, (301) 408– 

9756, carsteae@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Epidemiology and Public Health. 

Date: July 12, 2022. 

Time: 11:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Cynthia C. McOliver, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1007G, 

Bethesda, MD 20892, (301) 594–2081, 

mcolivercc@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Pain Neurobiology. 

Date: July 13, 2022. 

Time: 10:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Roger Janz, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 402–8515, janzr2@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; RFA–NS– 

22–034: HEAL Initiative. 

Date: July 13, 2022. 

Time: 3:00 p.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Roger Janz, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 402–8515, janzr2@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR Panel: 

Academic Industrial Partnerships for 

Translation of Medical Technologies. 

Date: July 14–15, 2022. 

Time: 9:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Steven Anthony Ripp, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 594–3010, steven.ripp@nih.gov. 

Name of Committee: Infectious Diseases 

and Immunology B Integrated Review Group; 

HIV Immunopathogenesis and Vaccine 

Development Study Section. 

Date: July 14–15, 2022. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Shiv A. Prasad, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5220, 

MSC 7852, Bethesda, MD 20892, 301–443– 

5779, prasads@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Cardiovascular Sciences. 

Date: July 14, 2022. 

Time: 11:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Sara Ahlgren, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Rm. 4136, 

Bethesda, MD 20892, 301–435–0904, 

sara.ahlgren@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; RFA–OD– 

22–006: RADx-UP Community-Engaged 

Research on Rapid SARS–CoV–2 Testing 

among Underserved and Vulnerable 

Populations. 

Date: July 15, 2022. 

Time: 11:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Annie L. McRee, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 100, 

Bethesda, MD 20892, (301) 827–7396, 

mcreeal@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Research 

Enhancement Awards: Genes, Genomes, and 

Genetics. 

Date: July 15, 2022. 

Time: 11:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Guoqin Yu, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 435–1276, guoqin.yu@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 


lotter on DSK11XQN23PROD with NOTICES1